Bioprinted 3D Primary Liver Tissues Allow Assessment of Organ-Level Response to Clinical Drug Induced Toxicity In Vitro
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Modeling clinically relevant tissue responses using cell models poses a significant challenge for drug development, in particular for drug induced liver injury (DILI). This is mainly because existing liver models lack longevity and tissue-level complexity which limits their utility in predictive toxicology. In this study, we established and characterized novel bioprinted human liver tissue mimetics comprised of patient-derived hepatocytes and non-parenchymal cells in a defined architecture. Scaffold-free assembly of different cell types in an in vivo-relevant architecture allowed for histologic analysis that revealed distinct intercellular hepatocyte junctions, CD31+ endothelial networks, and desmin positive, smooth muscle actin negative quiescent stellates. Unlike what was seen in 2D hepatocyte cultures, the tissues maintained levels of ATP, Albumin as well as expression and drug-induced enzyme activity of Cytochrome P450s over 4 weeks in culture. To assess the ability of the 3D liver cultures to model tissue-level DILI, dose responses of Trovafloxacin, a drug whose hepatotoxic potential could not be assessed by standard pre-clinical models, were compared to the structurally related non-toxic drug Levofloxacin. Trovafloxacin induced significant, dose-dependent toxicity at clinically relevant doses (≤ 4uM). Interestingly, Trovafloxacin toxicity was observed without lipopolysaccharide stimulation and in the absence of resident macrophages in contrast to earlier reports. Together, these results demonstrate that 3D bioprinted liver tissues can both effectively model DILI and distinguish between highly related compounds with differential profile. Thus, the combination of patient-derived primary cells with bioprinting technology here for the first time demonstrates superior performance in terms of mimicking human drug response in a known target organ at the tissue level.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3D bioprinting of tissues and organs
Murphy, S. V., & Atala, A. (2014) · Nature Biotechnology · doi:10.1038/nbt.2958 · Cited by 7,034
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842 · cited 1×
“While human and rodent HSCs maintained in standard monolayer culture on plastic undergo activation to a myofibroblast phenotype with concomitant upregulation of smooth muscle actin (α-SMA), the HSC resident in the interior of the 3D liver tissues express desmin and not α-SMA (Fig 3E and 3F), suggesting that they are c…”
BackgroundThe third dimension bridges the gap between cell culture and live tissue
Pampaloni, F., Reynaud, E. G., & Stelzer, E. H. K. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2236 · Cited by 2,817 · cited 1×
“While those techniques allow preservation of oxygen and nutrient diffusion, they also result in a higher proportion of contact with a solid surface versus cell-cell contact, which may accelerate loss of function in specialized cell types such as hepatocytes, and may result in aberrant responses to stimuli [20].”
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280 · cited 3×
“The rapid loss of function in isolated human hepatocytes and species differences are major limitations in predictive toxicology which can lead to unexpected adverse outcomes in the clinic [10, 11].”
BackgroundDavis, G. E., & Senger, D. R. (2005) · Circulation Research · doi:10.1161/01.res.0000191547.64391.e3 · Cited by 1,223
Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver
(1980) · Food and Cosmetics Toxicology · doi:10.1016/0015-6264(80)90206-0 · Cited by 691
Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver
Maddrey, W. C. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70192-2 · Cited by 646
Controlling cell interactions by micropatterning in co-cultures: Hepatocytes and 3T3 fibroblasts
Bhatia, S. N., Yarmush, M. L., & Toner, M. (1997) · Journal of Biomedical Materials Research · doi:10.1002/(sici)1097-4636(199702)34:2<189::aid-jbm8>3.0.co;2-m · Cited by 547
In vitro models for liver toxicity testing
Soldatow, V. Y., LeCluyse, E. L., Griffith, L. G., & Rusyn, I. (2013) · Toxicol. Res. · doi:10.1039/c2tx20051a · Cited by 472
Research works printed but not linked: 1
- DG Nguyen, 2016, Engineered Renal Tissues, Arrays Thereof, and Methods of Making the Same, United States of America Patent Office
Cited by
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Printability and shape fidelity of bioinks in 3D bioprinting
Schwab, A., Levato, R., D’Este, M., Piluso, S., Eglin, D., & Malda, J. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00084 · Cited by 1,359
Advances in organ-on-a-chip engineering
Zhang, B., Korolj, A., Lai, B. F. L., & Radisic, M. (2018) · Nature Reviews Materials · doi:10.1038/s41578-018-0034-7 · Cited by 1,017
Biofabrication: A Guide to Technology and Terminology
Moroni, L., Boland, T., Burdick, J. A., De Maria, C., Derby, B., Forgacs, G., Groll, J., Li, Q., Malda, J., Mironov, V. A., et al. (2018) · Trends in Biotechnology · doi:10.1016/j.tibtech.2017.10.015 · Cited by 636
3D bioprinting of tissues and organs for regenerative medicine
Vijayavenkataraman, S., Yan, W.-C., Lu, W. F., Wang, C.-H., & Fuh, J. Y. H. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.004 · Cited by 630
Current and emerging applications of 3D printing in medicine
Liaw, C.-Y., & Guvendiren, M. (2017) · Biofabrication · doi:10.1088/1758-5090/aa7279 · Cited by 604
Recent Advances in Bioink Design for 3D Bioprinting of Tissues and Organs
Ji, S., & Guvendiren, M. (2017) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2017.00023 · Cited by 490
Recent Advances in Extrusion‐Based 3D Printing for Biomedical Applications
Placone, J. K., & Engler, A. J. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701161 · Cited by 486
Organ-on-a-chip devices advance to market
Zhang, B., & Radisic, M. (2017) · Lab on a Chip · doi:10.1039/c6lc01554a · Cited by 437
3D Bioprinting: from Benches to Translational Applications
Heinrich, M. A., Liu, W., Jimenez, A., Yang, J., Akpek, A., Liu, X., Pi, Q., Mu, X., Hu, N., Schiffelers, R. M., et al. (2019) · Small · doi:10.1002/smll.201805510 · Cited by 437
Cellular extrusion bioprinting improves kidney organoid reproducibility and conformation
Lawlor, K. T., Vanslambrouck, J. M., Higgins, J. W., Chambon, A., Bishard, K., Arndt, D., Er, P. X., Wilson, S. B., Howden, S. E., Tan, K. S., et al. (2021) · Nature Materials · doi:10.1038/s41563-020-00853-9 · Cited by 435
Self-citationGeneration of expandable human pluripotent stem cell-derived hepatocyte-like liver organoids
Mun, S. J., Ryu, J.-S., Lee, M.-O., Son, Y. S., Oh, S. J., Cho, H.-S., Son, M.-Y., Kim, D.-S., Kim, S. J., Yoo, H. J., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.030 · Cited by 373
Bioprinting: From Tissue and Organ Development to in Vitro Models
Mota, C., Camarero-Espinosa, S., Baker, M. B., Wieringa, P., & Moroni, L. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00789 · Cited by 345
Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury
Proctor, W. R., Foster, A. J., Vogt, J., Summers, C., Middleton, B., Pilling, M. A., Shienson, D., Kijanska, M., Ströbel, S., Kelm, J. M., et al. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-2002-1 · Cited by 328
“…and Bhatia 2008; Khetani et al. 2013), three-dimensional (3D) bioprinted liver tissues comprised of several hepatic cell types (Ma et al. 2016; Nguyen et al. 2016), and 3D spheroid cultures either as mono-culture or co-culture with hepatic non-parenchymal cells (NPC) (Bell et al. 2016;…”
Background3D bioprinting for drug discovery and development in pharmaceutics
Peng, W., Datta, P., Ayan, B., Ozbolat, V., Sosnoski, D., & Ozbolat, I. T. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.05.025 · Cited by 313
Principles of the Kenzan Method for Robotic Cell Spheroid-Based Three-Dimensional Bioprinting
Moldovan, N. I., Hibino, N., & Nakayama, K. (2017) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2016.0322 · Cited by 296
Print Me An Organ! Why We Are Not There Yet
Ng, W. L., Chua, C. K., & Shen, Y.-F. (2019) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2019.101145 · Cited by 287
Natural Hydrogel-Based Bio-Inks for 3D Bioprinting in Tissue Engineering: A Review
Fatimi, A., Okoro, O. V., Podstawczyk, D., Siminska-Stanny, J., & Shavandi, A. (2022) · Gels · doi:10.3390/gels8030179 · Cited by 276
“To date, inkjet-based bioprinting has been utilized to create 3D tissues and biological constructs, including 3D replicas of cartilage [155], engineered neural tissues [126,129], brain tissue [127], renal tissue [128], 3D contractile smooth muscle tissues [125], skin tissue [137,138], air–blood tissue barrier [139], h…”
MethodApplications of 3D printing in healthcare
Dodziuk, H. (2016) · Polish Journal of Cardio-Thoracic Surgery · doi:10.5114/kitp.2016.62625 · Cited by 272
Emerging Technologies in Multi‐Material Bioprinting
Ravanbakhsh, H., Karamzadeh, V., Bao, G., Mongeau, L., Juncker, D., & Zhang, Y. S. (2021) · Advanced Materials · doi:10.1002/adma.202104730 · Cited by 266
3D Bioprinting of Human Tissues: Biofabrication, Bioinks, and Bioreactors
Zhang, J., Wehrle, E., Rubert, M., & Müller, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083971 · Cited by 257
Modeling tumor phenotypes in vitro with three-dimensional bioprinting
Langer, E. M., Allen-Petersen, B. L., King, S. M., Kendsersky, N. D., Turnidge, M. A., Kuziel, G. M., Riggers, R., Samatham, R., Amery, T. S., Jacques, S. L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.090 · Cited by 256
Self-citationLauschke, V. M., Hendriks, D. F. G., Bell, C. C., Andersson, T. B., & Ingelman-Sundberg, M. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00150 · Cited by 241
The arrival of commercial bioprinters – Towards 3D bioprinting revolution!
Choudhury, D., Anand, S., & Naing, M. W. (2024) · International Journal of Bioprinting · doi:10.18063/ijb.v4i2.139 · Cited by 189
Prantil-Baun, R., Novak, R., Das, D., Somayaji, M. R., Przekwas, A., & Ingber, D. E. (2018) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104748 · Cited by 176
Recent trends on biomaterials for tissue regeneration applications: Review
Farag, M. M. (2023) · Journal of Materials Science · doi:10.1007/s10853-022-08102-x · Cited by 173
“Eur Polymer J 121:109308 [125] Nguyen DG, Funk J, Robbins JB, Crogan-Grundy C,”
BackgroundLauschke, V. M., Shafagh, R. Z., Hendriks, D. F. G., & Ingelman‐Sundberg, M. (2019) · Biotechnology Journal · doi:10.1002/biot.201800347 · Cited by 153
Baudy, A. R., Otieno, M. A., Hewitt, P., Gan, J., Roth, A., Keller, D., Sura, R., Van Vleet, T. R., & Proctor, W. R. (2020) · Lab on a Chip · doi:10.1039/c9lc00768g · Cited by 150
Self-citationDrug Toxicity Evaluation Based on Organ-on-a-chip Technology: A Review
Cong, Y., Han, X., Wang, Y., Chen, Z., Lu, Y., Liu, T., Wu, Z., Jin, Y., Luo, Y., & Zhang, X. (2020) · Micromachines · doi:10.3390/mi11040381 · Cited by 140
A critical perspective on 3D liver models for drug metabolism and toxicology studies
Serras, A. S., Rodrigues, J. S., Cipriano, M., Rodrigues, A. V., Oliveira, N. G., & Miranda, J. P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.626805 · Cited by 138
In Vitro Models for Non-Alcoholic Fatty Liver Disease: Emerging Platforms and Their Applications
Ramos, M. J., Bandiera, L., Menolascina, F., & Fallowfield, J. A. (2022) · iScience · doi:10.1016/j.isci.2021.103549 · Cited by 127
Cuvellier, M., Ezan, F., Oliveira, H., Rose, S., Fricain, J.-C., Langouët, S., Legagneux, V., & Baffet, G. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120611 · Cited by 126
Challenges and Opportunities in the Design of Liver-on-Chip Microdevices
Ehrlich, A., Duche, D., Ouedraogo, G., & Nahmias, Y. (2019) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-060418-052305 · Cited by 125
Human biomimetic liver microphysiology systems in drug development and precision medicine
Gough, A., Soto-Gutierrez, A., Vernetti, L., Ebrahimkhani, M. R., Stern, A. M., & Taylor, D. L. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00386-1 · Cited by 117
Olgasi, C., Cucci, A., & Follenzi, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176215 · Cited by 100
Zhou, Y., Shen, J. X., & Lauschke, V. M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01093 · Cited by 85
Liver three-dimensional cellular models for high-throughput chemical testing
Yang, S., Ooka, M., Margolis, R. J., & Xia, M. (2023) · Cell Reports Methods · doi:10.1016/j.crmeth.2023.100432 · Cited by 75
Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction
Segovia-Zafra, A., Di Zeo-Sánchez, D. E., López-Gómez, C., Pérez-Valdés, Z., García-Fuentes, E., Andrade, R. J., Lucena, M. I., & Villanueva-Paz, M. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.013 · Cited by 70
Ekert, J. E., Deakyne, J., Pribul-Allen, P., Terry, R., Schofield, C., Jeong, C. G., Storey, J., Mohamet, L., Francis, J., Naidoo, A., et al. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220923332 · Cited by 68
Kammerer, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910214 · Cited by 59
Hendriks, D. F. G., Vorrink, S. U., Smutny, T., Sim, S. C., Nordling, Å., Ullah, S., Kumondai, M., Jones, B. C., Johansson, I., Andersson, T. B., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1860 · Cited by 57
Constructing biomimetic liver models through biomaterials and vasculature engineering
Lv, W., Zhou, H., Aazmi, A., Yu, M., Xu, X., Yang, H., Huang, Y. Y. S., & Ma, L. (2022) · Regenerative Biomaterials · doi:10.1093/rb/rbac079 · Cited by 45
In vitro functional models for human liver diseases and drug screening: beyond animal testing
Paradiso, A., Volpi, M., Rinoldi, C., Celikkin, N., Contessi Negrini, N., Bilgen, M., Dallera, G., Pierini, F., Costantini, M., Święszkowski, W., et al. (2023) · Biomaterials Science · doi:10.1039/d1bm01872h · Cited by 40
Kim, M. K., Jeong, W., Jeon, S., & Kang, H.-W. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1305023 · Cited by 38
Liver organoids: established tools for disease modeling and drug development
Sun, X.-C., Kong, D.-F., Zhao, J., Faber, K. N., Xia, Q., & He, K. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000105 · Cited by 37
Liver microsystems in vitro for drug response
Lee, J.-H., Ho, K.-L., & Fan, S.-K. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0575-0 · Cited by 33
Recent advances in models of immune-mediated drug-induced liver injury
Tasnim, F., Huang, X., Lee, C. Z. W., Ginhoux, F., & Yu, H. (2021) · Frontiers in Toxicology · doi:10.3389/ftox.2021.605392 · Cited by 32
Guo, K., & van den Beucken, T. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01317-2 · Cited by 28
Ware, B. R., Liu, J. S., Monckton, C. P., Ballinger, K. R., & Khetani, S. R. (2021) · Toxicological Sciences · doi:10.1093/toxsci/kfab018 · Cited by 25
Bioprinted Hydrogels for Fibrosis and Wound Healing: Treatment and Modeling
Guo, J. L., & Longaker, M. T. (2022) · Gels · doi:10.3390/gels9010019 · Cited by 23
“extrusion-printed liver models using a similar composition of cell phenotypes, producing 3D tissues that outperformed 2D cell-culture models in replicating native intercellular hepatocyte junctions and endothelial networks [59].”
BackgroundInfluentialSasikumar, S., Chameettachal, S., Kingshott, P., Cromer, B., & Pati, F. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c00994 · Cited by 18
Gao, Q., Yu, K., Chen, F., Lu, L., & Zhang, P. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102108 · Cited by 8
“Complex geometric structures can be fabricated with various biocompatible materials via a layer-by-layer printing process [3,4].”
Background
Metadata
- Authors
- Nguyen, D. G., Funk, J., Robbins, J. B., Crogan-Grundy, C., Presnell, S. C., Singer, T., & Roth, A. B.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-07-07
- Volume
- 11
- Issue
- 7
- Pages
- e0158674
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2462042948
- Cited by
- 379
- References
- 39
- FWCI
- 49.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.